Assessment of The Clinical Course of Dyspnea in Acute Heart Failure Patients

Terminated

• Conditions: Acute Heart Failure; Dyspnea

• Registration Number: NCT01615926
• Lead Sponsor: Northwestern University

Brief Summary

Acute heart failure (AHF) is defined as a gradual or rapid change in heart failure (HF) signs and symptoms, such as shortness of breath (also called dyspnea or breathlessness), leg swelling, fatigue, breathlessness with exertion, trouble sleeping flat at night, and weight gain resulting in a need for urgent therapy. AHF results in over 1 million hospitalizations every year, resulting in an enormous public health burden. Approximately 1/3rd of patients will either be re-hospitalized or die within three months, and the resultant financial costs are large. As such, improving outcomes for AHF patients is critically important. Shortness of breath is the most common reason why patients with AHF present to the ER. As such, understanding how severe this symptom is, how much it improves with current treatments is very important to both patients and physicians. The purpose of this study is to determine the degree to which your shortness of breath improves during the first few days of hospitalization and its association with how fast you are breathing.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2012-06
• Study First Submitted: 2012-06-07
• Study First Submitted QC: 2012-06-07
• Study First Posted: 2012-06-11
• Primary Completion: 2012-08
• Study Completion: 2012-08
• Status Verified: 2013-04
• Last Update Submitted: 2013-04-30
• Last Update Posted: 2013-05-01

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 16

Inclusion Criteria

• Male or female ≥ 18 years of age
• AHFS is the primary working diagnosis for ER management and treatment with planned admission
• Have received IV diuretic therapy
• Enrolled within 3 hours of initial diuretic dose

Read More

Exclusion Criteria

• BNP level is ≤ 300 pg/mL (may be initially enrolled and then will be excluded for second assessment)
• Transplant recipients of any kind
• Fever > 101.5
• Severe lung disease (required home O2 or daily oral steroids)
• Any ACS event within last 30 days
• Life expectancy less than 12 months for any reason
• Current treatment for any malignancy of any kind
• Cardiogenic shock and/or requiring IV inotropic therapy
• Pregnant or recently pregnant within last 90 days
• Inability to give appropriate written consent

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To determine the association between respiratory rate and self-reported dyspnea in AHF patients.	24 hours

Trial Locations

Locations (1)

Northwestern Memorial Hospital; 🇺🇸 Chicago, Illinois, United States